BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 18997048)

  • 21. A simplified synthesis of the hypoxia imaging agent 2-(2-Nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-[(18)F]pentafluoropropyl)-acetamide ([18F]EF5).
    Chitneni SK; Bida GT; Dewhirst MW; Zalutsky MR
    Nucl Med Biol; 2012 Oct; 39(7):1012-8. PubMed ID: 22727821
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy.
    Eschmann SM; Paulsen F; Reimold M; Dittmann H; Welz S; Reischl G; Machulla HJ; Bares R
    J Nucl Med; 2005 Feb; 46(2):253-60. PubMed ID: 15695784
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients.
    Troost EG; Vogel WV; Merkx MA; Slootweg PJ; Marres HA; Peeters WJ; Bussink J; van der Kogel AJ; Oyen WJ; Kaanders JH
    J Nucl Med; 2007 May; 48(5):726-35. PubMed ID: 17475960
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dynamics of tumor hypoxia assessed by 18F-FAZA PET/CT in head and neck and lung cancer patients during chemoradiation: possible implications for radiotherapy treatment planning strategies.
    Bollineni VR; Koole MJ; Pruim J; Brouwer CL; Wiegman EM; Groen HJ; Vlasman R; Halmos GB; Oosting SF; Langendijk JA; Widder J; Steenbakkers RJ
    Radiother Oncol; 2014 Nov; 113(2):198-203. PubMed ID: 25434768
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quantifying tumour hypoxia with fluorine-18 fluoroerythronitroimidazole ([18F]FETNIM) and PET using the tumour to plasma ratio.
    Lehtiö K; Oikonen V; Nyman S; Grönroos T; Roivainen A; Eskola O; Minn H
    Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):101-8. PubMed ID: 12483416
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of hypoxia in human squamous cell carcinoma by EF5 binding.
    Evans SM; Hahn S; Pook DR; Jenkins WT; Chalian AA; Zhang P; Stevens C; Weber R; Weinstein G; Benjamin I; Mirza N; Morgan M; Rubin S; McKenna WG; Lord EM; Koch CJ
    Cancer Res; 2000 Apr; 60(7):2018-24. PubMed ID: 10766193
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Initial results of hypoxia imaging using 1-alpha-D: -(5-deoxy-5-[18F]-fluoroarabinofuranosyl)-2-nitroimidazole ( 18F-FAZA).
    Postema EJ; McEwan AJ; Riauka TA; Kumar P; Richmond DA; Abrams DN; Wiebe LI
    Eur J Nucl Med Mol Imaging; 2009 Oct; 36(10):1565-73. PubMed ID: 19430784
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Two or four hour [¹⁸F]FMISO-PET in HNSCC. When is the contrast best?
    Abolmaali N; Haase R; Koch A; Zips D; Steinbach J; Baumann M; Kotzerke J; Zöphel K
    Nuklearmedizin; 2011; 50(1):22-7. PubMed ID: 21165537
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Utility of 19F MRS detection of the hypoxic cell marker EF5 to assess cellular hypoxia in solid tumors.
    Salmon HW; Siemann DW
    Radiother Oncol; 2004 Dec; 73(3):359-66. PubMed ID: 15588883
    [TBL] [Abstract][Full Text] [Related]  

  • 30. pO(2) Polarography versus positron emission tomography ([(18)F] fluoromisonidazole, [(18)F]-2-fluoro-2'-deoxyglucose). An appraisal of radiotherapeutically relevant hypoxia.
    Gagel B; Reinartz P; Dimartino E; Zimny M; Pinkawa M; Maneschi P; Stanzel S; Hamacher K; Coenen HH; Westhofen M; Büll U; Eble MJ
    Strahlenther Onkol; 2004 Oct; 180(10):616-22. PubMed ID: 15480509
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Imaging of tumor hypoxia to predict treatment sensitivity.
    Minn H; Grönroos TJ; Komar G; Eskola O; Lehtiö K; Tuomela J; Seppänen M; Solin O
    Curr Pharm Des; 2008; 14(28):2932-42. PubMed ID: 18991711
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Geometric analysis of loco-regional recurrences in relation to pre-treatment hypoxia in patients with head and neck cancer.
    Boeke S; Thorwarth D; Mönnich D; Pfannenberg C; Reischl G; La Fougère C; Nikolaou K; Mauz PS; Paulsen F; Zips D; Welz S
    Acta Oncol; 2017 Nov; 56(11):1571-1576. PubMed ID: 28891398
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 18F-FET PET compared with 18F-FDG PET and CT in patients with head and neck cancer.
    Pauleit D; Zimmermann A; Stoffels G; Bauer D; Risse J; Flüss MO; Hamacher K; Coenen HH; Langen KJ
    J Nucl Med; 2006 Feb; 47(2):256-61. PubMed ID: 16455631
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prospective comparison of 18F-FDG PET with conventional imaging modalities (MRI, CT, and 67Ga scintigraphy) in assessment of combined intraarterial chemotherapy and radiotherapy for head and neck carcinoma.
    Kitagawa Y; Nishizawa S; Sano K; Ogasawara T; Nakamura M; Sadato N; Yoshida M; Yonekura Y
    J Nucl Med; 2003 Feb; 44(2):198-206. PubMed ID: 12571209
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 trial.
    Mortensen LS; Johansen J; Kallehauge J; Primdahl H; Busk M; Lassen P; Alsner J; Sørensen BS; Toustrup K; Jakobsen S; Petersen J; Petersen H; Theil J; Nordsmark M; Overgaard J
    Radiother Oncol; 2012 Oct; 105(1):14-20. PubMed ID: 23083497
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patterns and levels of hypoxia in head and neck squamous cell carcinomas and their relationship to patient outcome.
    Evans SM; Du KL; Chalian AA; Mick R; Zhang PJ; Hahn SM; Quon H; Lustig R; Weinstein GS; Koch CJ
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1024-31. PubMed ID: 17967299
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer.
    Grosu AL; Souvatzoglou M; Röper B; Dobritz M; Wiedenmann N; Jacob V; Wester HJ; Reischl G; Machulla HJ; Schwaiger M; Molls M; Piert M
    Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):541-51. PubMed ID: 17869667
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biodistribution of the nitroimidazole EF5 (2-[2-nitro-1H-imidazol-1-yl]-N-(2,2,3,3,3-pentafluoropropyl) acetamide) in mice bearing subcutaneous EMT6 tumors.
    Laughlin KM; Evans SM; Jenkins WT; Tracy M; Chan CY; Lord EM; Koch CJ
    J Pharmacol Exp Ther; 1996 May; 277(2):1049-57. PubMed ID: 8627516
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A prospective clinical study of ¹⁸F-FAZA PET-CT hypoxia imaging in head and neck squamous cell carcinoma before and during radiation therapy.
    Servagi-Vernat S; Differding S; Hanin FX; Labar D; Bol A; Lee JA; Grégoire V
    Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1544-52. PubMed ID: 24570097
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospective feasibility trial of radiotherapy target definition for head and neck cancer using 3-dimensional PET and CT imaging.
    Scarfone C; Lavely WC; Cmelak AJ; Delbeke D; Martin WH; Billheimer D; Hallahan DE
    J Nucl Med; 2004 Apr; 45(4):543-52. PubMed ID: 15073248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.